On October 22, 2020 Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a Phase 3 clinical-stage biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications, reported that it intends to offer and sell common shares and, to certain investors in lieu thereof, pre-funded warrants to purchase common shares, in an underwritten public offering (Press release, Milestone Pharmaceuticals, OCT 22, 2020, View Source [SID1234568874]). All of the securities in the offering will be sold by Milestone. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies and Piper Sandler are acting as joint book-running managers for the offering. Milestone expects to grant the underwriters a 30-day option to purchase additional common shares in the proposed offering of up to 15% of the aggregate number of common shares plus the common shares underlying the pre-funded warrants being offered in the offering.

Milestone intends to use the net proceeds from the offering primarily to fund the clinical development of its lead product candidate etripamil, and for working capital, capital expenditures and other general corporate purposes.

The securities described above are being offered by Milestone pursuant to a shelf registration statement on Form S-3 (File No. 333-239318) filed with the Securities and Exchange Commission ("SEC") on June 19, 2020 and declared effective by the SEC on July 6, 2020. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website at View Source Copies of the preliminary and final prospectus supplements relating to the offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On October 22, 2020 Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, reported that the Company will release its financial results for the third quarter ended September 30, 2020 after the market closes on November 5, 2020 (Press release, Nevro, OCT 22, 2020, View Source [SID1234568873]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will host a conference call on November 5, 2020 to discuss third quarter 2020 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET. Investors interested in listening to the call may do so by dialing (866) 324-3683 in the U.S. or +1 (509) 844-0959 internationally, using Conference ID: 6693376. In addition, a live webcast, as well as an archived recording, will be available on the "Investors" section of the Company’s website at: www.nevro.com.

On October 22, 2020 Universal Health Services, Inc. (NYSE: UHS) reported that it will report results for its third quarter ended September 30, 2020 after the market closes on­­­­­­ Thursday, October 29, 2020 (Press release, Universal Health Services, OCT 22, 2020, View Source [SID1234568872]). There will be a conference call for investors and analysts at 10:00 a.m. Eastern Time on Friday, October 30, 2020. The dial-in number is 1-877-648-7971.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live broadcast of the conference call will be available on the company’s website at www.uhsinc.com. Also, a replay of the call will be available following the conclusion of the live call for one full year.

Universal Health Services, Inc. is one of the nation’s largest hospital companies operating through its subsidiaries acute care hospitals, behavioral health facilities and ambulatory centers located throughout the United States, the United Kingdom, and Puerto Rico.

On October 22, 2020 Be Biopharma ("Be Bio"), a leader in developing B cells as medicines, founded by Longwood Fund, David Rawlings, MD, and Richard James, PhD, reported a $52 million Series A financing led by Atlas Venture and RA Capital Management and joined by Alta Partners, Longwood Fund and Takeda Ventures, Inc (Press release, Be Biopharma, OCT 22, 2020, View Source [SID1234568871]). The company plans to use this funding to precisely engineer B cells to treat a range of diseases, building on the pioneering work of Drs. Rawlings and James at Seattle Children’s Research Institute. B cells are prolific protein producers that can be collected from peripheral blood, have a programmable lifetime that could last decades, can target specific tissues, and have broad, customizable functionality.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Be Bio is capitalizing on the unique attributes of B cells to create a new category of medicine that is distinct from traditional cell or gene therapy," said David Steinberg, Chief Executive Officer, co-founder and Director, Be Biopharma and General Partner, Longwood Fund. "B cells can be engineered to express a wide variety of proteins, have the potential to generate durable responses, and can be dose-titrated and administered multiple times without the need for toxic preconditioning. Moreover, the varied functions of B cells suggest that B cell medicines can address a range of conditions including autoimmune diseases, cancer, and monogenic disorders, as well as enhance the immune response to infectious pathogens. We believe Be Bio is at the forefront of a new approach to fighting disease."

"B cells play a key role in combatting diseases by catalyzing humoral immunity – the arm of the immune system that manufactures large quantities of proteins to neutralize disease-causing pathogens and manipulate immune cell behavior," said Be Biopharma co-founder David Rawlings, MD, Director, Center for Immunity and Immunotherapies, Seattle Children’s Research Institute and Professor of Pediatrics, University of Washington School of Medicine. "Today, this powerful part of the immune system is only passively and/or indirectly addressed therapeutically. Our ambition is to advance the field by building a new class of engineered B cell medicines that will provide direct control over the power of humoral immunity and help transform the prognosis for patients who currently have limited treatment options."

In addition to Rawlings, James and Steinberg, Be Bio’s co-founders are Aleks Radovic-Moreno, PhD, President and Director, and Lea Hachigian, PhD, with Longwood Fund. The Board of Directors also includes Josh Resnick, MD, MBA, Managing Director, RA Capital Management; Jason Rhodes, Partner, Atlas Venture; and Dan Janney, MBA, Managing Partner, Alta Partners.

Be Biopharma’s Scientific Advisory Board consists of David Rawlings MD; Richard James, PhD, Principal Investigator, Seattle Children’s Research Institute and Associate Professor, Department of Pediatrics, University of Washington, as well as Frances Eun-Hyung Lee, MD, an Asthma, Allergy, and Immunology physician and researcher in Atlanta, GA; Shiv Pillai, MD, PhD, Professor, Harvard Medical School, Investigator Ragon Institute, Director, Autoimmune Center of Excellence, Massachusetts General Hospital; and Jason Cyster, PhD, Professor, Department of Microbiology and Immunology, University of California San Francisco.

On October 22, 2020 Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, reported that it will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, Nov. 5, 2020, following the release of its third quarter 2020 financial results (Press release, Puma Biotechnology, OCT 22, 2020, View Source [SID1234568870]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at View Source A replay of the call will be available shortly after completion of the call and will be archived on Puma’s website for 90 days.